SARS-CoV-2 (COVID-19) NSP16 Peptide

Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1) . The disease is the cause of the 2019–20 coronavirus outbreak (2) . The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Methyltransferase mediates mRNA cap 2'-O-ribose methylation to the 5'-cap structure of viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of nsp16. Therefore plays an essential role in viral mRNAs cap methylation which is essential to evade immune system.

43740578

P0DTC1

YP_009725311

Peptides

200 ug/mL

PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide

Blue Ice

Store SARS-CoV-2 (COVID-19) NSP16 Peptide at -20˚ C, stable for one year.

SARS-CoV-2 (COVID-19) NSP16 Peptideis used for blocking the activity of theSARS-CoV-2 (COVID-19) NSP16 Antibody

ORF1a polyprotein; ORF1ab polyprotein

Severe acute respiratory syndrome coronavirus 2

Gorbalenya. bioRxiv: 2020.

Hui et al. Int J Infect Dis. 2020;91:264-266.

2'-O-methyltransferase, nsp16, Non-structure protein 16

Blocking

SARS-CoV-4

1819735431

Liquid